The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public. 

The Aventus Thrombectomy System was already cleared to treat blood clots in the peripheral arteries. This latest approval comes after positive results from an IDE study were published in JSCAI.

The new name will be familiar to anyone who knows the history of Medtronic's diabetes business.

The doctor is accused of using fake credentials for several months and performing approximately 50 procedures. This is the second time in recent months someone has been accused of impersonating a heart specialist and treating patients.

“Just as medicine has its own language, so does business," two surgeons explained in a new editorial. 

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts.

The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use. 

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

Use of the drug more than doubles a person's risk of dying from heart disease, according to a new analysis of 24 different studies. In a separate editorial, two physicians shared their concerns and highlighted the importance of discussing these risks with patients.